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Abstract
Background Breast, cervical and colorectal cancers are
the three most frequent cancers in women, while lung,
prostate and colorectal cancers are the most frequent in
men. Much attention has been given to the economic
evaluation of pharmaceuticals for treatment of cancer by
the National Institute for Health and Care Excellence
(NICE) in the UK and similar authorities internationally,
while economic analysis developed for other types of anti-
cancer interventions, including radiotherapy and surgery,
are less common.
Objectives Our objective was to review methods used in
published cost-effectiveness studies evaluating radiother-
apy for breast, cervical, colorectal, head and neck and
prostate cancer, and to compare the economic evaluation
methods applied with those defined in the guidelines used
by the NICE technology appraisal programme.
Methods A systematic search of seven databases (MED-
LINE, EMBASE, CDSR, NHSEED, HTA, DARE, Econ-
Lit) as well as research registers, the NICE website and
conference proceedings was conducted in July 2012. Only
economic evaluations of radiotherapy interventions in
individuals diagnosed with cancer that included quality-
adjusted life-years (QALYs) or life-years (LYs) were
included. Included studies were appraised on the basis of
satisfying essential, preferred and UK-specific methods
requirements, building on the NICE Reference Case for
economic evaluations and on other methods guidelines.
Results A total of 29 studies satisfied the inclusion cri-
teria (breast 14, colorectal 2, prostate 10, cervical 0, head
and neck 3). Only two studies were conducted in the UK
(13 in the USA). Among essential methods criteria, the
main issue was that only three (10 %) of the studies used
clinical-effectiveness estimates identified through system-
atic review of the literature. Similarly, only eight (28 %)
studies sourced health-related quality-of-life data directly
from patients with the condition of interest. Other essential
criteria (e.g. clear description of comparators, patient group
indication and appropriate time horizon) were generally
fulfilled, while most of the UK-specific requirements were
not met.
Conclusion Based on this review there is a dearth of up-
to-date, robust evidence on the cost effectiveness of
radiotherapy in cancer suitable to support decision making
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in the UK. Studies selected did not fully satisfy essential
method standards currently recommended by NICE.
Key Points for Decision Makers
Few studies were found that examine the cost
effectiveness of radiotherapy for breast, cervical,
colorectal, head and neck and prostate cancer, and
only two analyses were conducted in the UK.
Additional, high-quality evidence is required to
inform decision making on the effectiveness and
cost-effectiveness of radiotherapy in cancer.
Many recent publications identified in the review did
not satisfy essential methods requirements.
Forthcoming economic evaluations of radiotherapy
in cancer should adhere to such requirements to
better inform decision makers.
1 Introduction
Economic evaluations are increasingly used to inform
decisions about the efficient allocation of healthcare
resources. To date, these methods have mainly been
applied to evaluate pharmaceutical interventions. Less
evidence is available for other types of intervention, such
as medical devices, surgical techniques and public health
interventions, and decision making in these cases appears
more challenging [1, 2]. The National Institute for Health
and Care Excellence (NICE) in the UK represents an
independent organisation tasked with assessing the clinical
and cost effectiveness of health technologies and, to date,
has mainly focused on new pharmaceutical and biophar-
maceutical products. However, the scope of their respon-
sibilities continues to expand and now includes diagnostics,
public health interventions and social care.
NICE has issued a Reference Case for cost effectiveness
in technnology appraisal, which specifies the methods
standards considered to be consistent with a UK National
Health Service (NHS) objective of improving population
health given limited resources and a fixed budget. An
element that distinguishes NICE from most other agencies
is the explicit statement of a cost-effectiveness threshold,
in terms of cost per quality-adjusted life-year (QALY)
gained (£20,000–30,000), to classify interventions as good
value for money.
Cancer is a leading cause of morbidity and mortality
worldwide. An estimated 12.7 million new cases of cancer
were diagnosed worldwide in 2008, with 7.6 million can-
cer-specific deaths (around 13 % of all deaths) [3]. Breast,
cervical and colorectal cancers are the three most frequent
cancers in women, while lung, prostate and colorectal
cancers are the most frequent in men [3]. Much attention
has been given to the economic evaluation of pharmaceu-
ticals for treatment of cancer by NICE and similar
authorities internationally. This contrasts markedly with
the level of economic analysis developed for other types of
anti-cancer interventions, including radiotherapy and sur-
gery. For example, of the 35 NICE appraisals of breast
cancer interventions, 28 (80 %) were technology appraisals
of pharmaceuticals and seven (20 %) were non-
pharmaceuticals.
Originally undertaken to inform the UK Department of
Health, the aim of this review was to assess the quality of
published economic evaluation studies of radiotherapy in
breast, cervical, prostate, head and neck and colorectal
cancers. Critical assessment of the studies was in terms of
their reporting and conduct, including whether or not they
adhered to methods standards for economic evaluation.
There was also an assessment of whether the studies would
provide relevant evidence for decisions in a UK setting.
2 Methods
Five systematic literature reviews were undertaken of the
published evidence on the economic evaluation of radio-
therapy in breast, cervical, prostate, head and neck, or
colorectal cancer in July 2012. To identify relevant evi-
dence, the following databases were searched: MEDLINE,
EMBASE, Cochrane Database of Systematic Reviews
(CDSR), NHS Economic Evaluation Database (NHSEED),
Health Technology Assessment (HTA), Database of
Abstracts of Reviews of Effects (DARE), and EconLit.
Additionally, the Cost-Effectiveness Analysis (CEA) reg-
istry (https://research.tufts-nemc.org/cear4/), the NICE
website (www.nice.org.uk), recent conference proceedings
and reference lists of the included studies and existing
reviews were also searched (see Appendix 1, with breast
cancer as an example).
Citations retrieved by the searches were filtered by title
and abstract, and the full manuscripts were retrieved if they
satisfied the inclusion criteria. Studies were included in the
review if they assessed the cost effectiveness of a radio-
therapy intervention in individuals with breast, colorectal,
cervical, head and neck or prostate cancer, and presented
results in the form of either an incremental cost per QALY
gained or an incremental cost per life-year (LY) gained. No
language, publication or date restrictions were applied to
the searches. Evidence was reviewed by a single researcher
(MB) in close consultation with another author (HW) and,
where there was any uncertainty, the issues were discussed
within the review team until a consensus was achieved.
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A data extraction template was designed to include rele-
vant information from the studies identified including set-
ting, patient population, intervention and comparators, type
of economic analysis (e.g. model-based vs. based on a clin-
ical study) and results. Included studies were appraised on
the basis of satisfying essential, preferred and UK-specific
methods requirements. The checklist draws heavily on the
NICE Reference Case for economic evaluations. In addition,
it draws on the authors’ experience of undertaking economic
evaluations, working with decision makers to use economic
evaluations to inform decisions and authors’ knowledge of
the published literature on checklists and methods guidelines
issued by other decision-making organisations. The aim was
to review the report and conduct of included economic
evaluations, focusing on the quality of each study to inform
decision making. As such, the checklist is concise and
designed as a decision aid, clearly distinguishing where
essential and preferred requirements are met, as explained
below. Those methods standards for economic evaluation
that are generally recommended as best practice for under-
taking a high-quality study were considered as essential
requirements, and include the following seven:
1. Comparators clearly defined and justified: the study
should provide a transparent and detailed description
of the interventions considered, justifying the choice of
comparators with relevance to, for example, clinical
practice or best practice. For example NICE guidelines
[4] state that, in order to define the decision problem
‘‘a definition and justification of the technologies being
compared’’ (page 31) is needed. Similarly, the Cana-
dian guidelines issued by the Canadian Agency for
Drugs and Technologies in Health (CADTH) [5] state
that ‘‘it is crucial to select the appropriate comparators
for the analysis, as the choice will be important in
determining the cost-effectiveness of the intervention’’
(page 16). Other guidelines, for example those of the
Academy of Managed Care Pharmacy (AMCP) [6] in
the USA and the Pharmaceutical Management Agency
(PHARMAC) [7] in New Zealand, specify which
comparator to use in the analysis (for example, ‘‘the
treatment that most prescribers would replace in New
Zealand,’’ page 8).
2. Patient group/indication clearly described: a clear
description of the characteristics of the patient group
receiving the interventions should be provided. For
example, NICE states that the decision problem is
supported by ‘‘a definition and justification of the
relevant patient group (s) to be treated’’ (page 31).
Some guidelines (e.g. NICE, CADTH, those issued by
the Pharmaceutical Benefits Advisory Committee
[PBAC] [8] in Australia) also highlight the importance
of defining potential subgroups.
3. Effectiveness evidence based on a systematic review:
evidence of a full literature search and, where appro-
priate, a synthesis of evidence on health effects
informed by systematic review, are recommended by
most economic guidelines (e.g. CADTH, PBAC,
NICE, AMCP, the Healthcare Insurance Board
(CVZ) [9] in the Netherlands). This ensures the data
used represent all the relevant published evidence
available at the time of the study, and helps to
minimise bias. Data synthesis methods such as meta-
analysis are recommended as appropriate. For exam-
ple, the NICE reference case states that ‘‘evidence on
outcomes should be obtained from a systematic
review, defined as the systematic location, inclusion,
appraisal and synthesis of evidence to obtain a reliable
and valid overview of the data related to a clearly
formulated question…. Synthesis of outcome data
through meta-analysis is appropriate provided there are
sufficient relevant and valid data that use measures of
outcome that are comparable.’’
4. Data for measurement of health-related quality of life
(HRQoL) reported directly by patients and/or carers:
it is generally recommended (e.g. NICE, Spanish
guidelines [10], PHARMAC) that information on
changes in HRQoL should be reported directly by
patients with the condition under analysis, or by their
carers when it is not possible to obtain these data
directly from patients. The NICE reference case states
that the ‘‘measurement of changes in HRQL should be
reported directly from patients.’’
5. Appropriate time horizon: the time horizon should be
long enough to reflect all important differences in costs
or outcomes between the interventions being com-
pared. In the case of cancer, a lifetime horizon is
typically the most appropriate, as the interventions
could potentially have an effect on survival duration.
6. Relevant one-way sensitivity analyses: this is neces-
sary to capture the full range of uncertainty that is
relevant for key (model) inputs. In some circum-
stances, alternative scenarios and worst/best cases
should be considered. Essentially, all guidelines for
economic evaluation recommend the use of at least a
one-way sensitivity analysis for key uncertain
parameters.
7. Probabilistic sensitivity analysis (PSA) used to quan-
tify full uncertainty: PSA is considered the most
appropriate technique to analyse joint uncertainty in all
parameters. Although only NICE recommends PSA for
submissions, this is also encouraged by other agencies
(AMCP, CADTH, CVZ).
Two methods features are more controversial but pre-
ferred for economic evaluation in many settings:
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(1) CEA using QALYs: although the use of a CEA based
on QALYs is often stated as the preferred option to
account for the impact of an intervention on HRQoL
and survival duration using a consistent generic
measure of outcome, this is not always seen as
mandatory by all international agencies.
(2) Preference data for valuation of HRQoL health states
by a representative sample of the public: although
some agencies (e.g. NICE, CADTH) recommend that
the valuation of HRQoL should be based on the
preferences of a representative sample of the general
public, this is not always seen as mandatory, and
valuation from patients, carers or health professionals
are accepted alternatives by some agencies.
Finally, a secondary objective of the review was to
assess the relevance of the studies identified from a UK
decision-making perspective. The NICE Reference Case
defines five areas of methods that can be considered spe-
cific to decision making in the NHS:
(1) Comparators used in the UK NHS at the time each
study was undertaken
(2) Decision problem and analysis relating to a UK
setting
(3) Cost perspective of UK NHS and personal social
services costs
(4) Discount rate of 3.5 % per annum for costs and
outcomes
(5) Cost per QALY below the NICE threshold value
(£20,000–30,000 per QALY).
The last point assesses if the intervention(s) analysed
would be considered cost effective in the UK context
3 Results
3.1 Results of the Review
A flow diagram of the results of the searches is presented in
Fig. 1. A total of 3,358 titles and abstracts were initially
identified (breast 794, colorectal 623, prostate 707, cervical
325, head and neck 909). After excluding duplicates and
studies that did not meet inclusion criteria, 116 full papers
were retrieved (breast 18, colorectal 18, prostate 37, cer-
vical 13, head and neck 30). Of these, 29 satisfied the
inclusion criteria and were included in the review (breast
14 [11–24], colorectal 2 [25, 26], prostate 10 [11, 27–35],
cervical 0, head and neck 3 [11, 29, 36]).
Of the studies, 13 (45 %) were undertaken in the USA,
and only two (7 %) studies were set in the UK. A total of
14 (48 %) of the studies selected were published a decade
or more before this review. Most analyses expressed cost
effectiveness in terms of incremental costs per QALY.
There was some variation in the interventions considered in
the analyses (especially for breast and prostate cancer).
Study characteristics and the main results for each study
are presented in Table 1. To judge the relevance of these
findings to the UK setting and to assess the quality of the
studies included, the numbers of studies that met essential,
preferred and UK-specific requirements were examined.
Figure 2 illustrates findings for each study included.
3.2 Essential Requirements
Among the seven criteria that were defined as essential
requirements, four were met in the majority of studies;
these were comparators clearly defined, patient group/
indication clearly defined, appropriate time horizon and
relevant one-way sensitivity analyses. In 27 (93 %) of the
studies, the interventions/comparators of the analysis were
clearly defined. The two studies without a clear description
of the interventions compared were both in prostate cancer
(Neymark et al. [27] and Basu and Meltzer [31]). These
studies focused on methods as opposed to generating
results to inform decision making. As such, the failure to
specify the options being compared can perhaps be
understood.
The interventions compared could be grouped into eight
broad categories: radiotherapy techniques in early-stage
breast cancer patients following conserving surgery; post-
mastectomy radiotherapy versus no radiotherapy in breast
cancer patients; the comparison of alternative radiotherapy
techniques in patients with breast cancer; radiotherapy
options for colorectal cancer; radiotherapy versus surgery
in early prostate cancer; different radiotherapy techniques
in patients with prostate cancer; radiotherapy plus hormone
therapies in locally advanced prostate cancer and palliative
treatments; and comparison of radiotherapy techniques for
head and neck cancer. Only in the methods paper by Basu
and Meltzer [31] was there no clear description of the
patient population (defined only as prostate cancer
patients). In the other studies, patients’ general character-
istics were reported, at least in terms of disease severity.
Given the potential impact of radiotherapy on mortality
risk, the most appropriate time horizon is likely to be
patients’ lifetime. A long-term time horizon (longer than
10 years) was used in 23 (79 %) studies, while six (21 %)
studies [12, 26, 31, 27, 32, 38] adopted a relatively short
time horizon of between 1 and 8 years or did not clearly
specify the time horizon of the analysis. Finally, one-way
sensitivity analyses were conducted in the majority of
studies (24 [83 %]), and the impact of variations in key
parameters on cost-effectiveness results was reported.
Other accepted requirements for methods standards
were not generally met. First, clinical data were obtained
from a systematic review of the literature in only 3 of the
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29 (10 %) studies (Hummel et al. [28] for prostate cancer;
Konski and Watkins-Bruner [32] for both prostate and head
and neck). In one study [15], data were obtained from a
published meta-analysis; 13 studies (45 %) obtained clin-
ical data from a single study (generally a clinical trial),
while the remaining analyses were informed by data from
various sources either selectively chosen by the authors or
not fully described.
The data for measurement of HRQoL were reported
directly by patients and/or carers in 5 of 26 studies (19 %).
In three studies, HRQoL was not considered. In 7 of 26
(27 %) cases, data were taken from a mixture of patients’
and experts’ judgements. In the remaining 14 of 26 (54 %)
cases, data were taken from previously published analyses
and it was not possible to tell who was involved in the
measurement task.
Finally, PSA was performed in only 10 of 29 studies.
Six of the 19 studies without a PSA were conducted before
2001 when this technique was not commonly used, but the
remaining 13 studies were published more recently.
3.3 Preferred Requirements
QALYs were used as the main outcome measure in 26 of
29 cases (90 %). The inclusion of HRQoL preference data
valued by a representative sample of the public was rare,
Fig. 1 Flow diagram for study
inclusion
Quality of EEs of Radiotherapy in Cancer 501
T
a
b
le
1
C
h
ar
ac
te
ri
st
ic
s
o
f
st
u
d
ie
s
in
cl
u
d
ed
R
ef
er
en
ce
s
S
et
ti
n
g
P
o
p
u
la
ti
o
n
In
te
rv
en
ti
o
n
C
o
m
p
ar
at
o
r
S
tu
d
y
d
es
ig
n
M
ai
n
fi
n
d
in
g
s
B
re
a
st
ca
n
ce
r
A
lv
eg
ar
d
et
al
.,
2
0
0
5
[2
2
]
S
w
ed
en
S
ta
g
e
I–
II
B
C
P
o
st
o
p
er
at
iv
e
R
T
N
o
R
T
M
o
d
el
(n
o
t
ex
p
li
ci
t)
P
o
st
-o
p
er
at
iv
e
R
T
is
co
st
ef
fe
ct
iv
e
w
h
en
u
se
d
as
ad
ju
n
ct
io
n
to
n
o
m
ed
ic
al
ad
ju
v
an
t
tx
an
d
in
h
ig
h
-r
is
k
p
ts
D
u
n
sc
o
m
b
e
et
al
.,
2
0
0
0
[2
0
]
C
an
ad
a
P
re
m
en
o
p
au
sa
l
n
o
d
e-
p
o
si
ti
v
e
B
C
A
d
ju
v
an
t
lo
co
re
g
io
n
al
R
T
(R
T
p
lu
s
su
rg
er
y
an
d
ch
em
o
th
er
ap
y
)
N
o
R
T
S
p
re
ad
sh
ee
t-
b
as
ed
ac
ti
v
it
y
-
co
st
in
g
m
o
d
el
A
d
ju
v
an
t
R
T
is
a
co
st
-e
ff
ec
ti
v
e
tx
H
ay
m
an
et
al
.,
1
9
9
8
[1
3
]
U
S
A
S
ta
g
e
I–
II
B
C
A
d
ju
v
an
t
R
T
N
o
R
T
M
ar
k
o
v
m
o
d
el
R
T
is
co
st
ef
fe
ct
iv
e
fo
ll
o
w
in
g
co
n
se
rv
at
iv
e
su
rg
er
y
H
ay
m
an
et
al
.,
2
0
0
0
[1
4
]
U
S
A
S
ta
g
e
I–
II
B
C
A
d
d
in
g
an
el
ec
tr
o
n
-b
ea
m
b
o
o
st
to
ta
n
g
en
ti
al
R
T
R
T
w
it
h
o
u
t
ta
n
g
en
ti
al
b
o
o
st
M
ar
k
o
v
m
o
d
el
B
o
o
st
is
n
o
t
co
st
ef
fe
ct
iv
e
u
si
n
g
a
th
re
sh
o
ld
o
f
$
5
0
,0
0
0
p
er
Q
A
L
Y
L
ee
et
al
.,
2
0
0
2
[1
5
]
U
S
A
H
ig
h
-r
is
k
p
re
m
en
o
p
au
sa
l
n
o
d
e-
p
o
si
ti
v
e
B
C
P
M
R
T
N
o
P
M
R
T
M
ar
k
o
v
m
o
d
el
P
M
R
T
is
co
st
-e
ff
ec
ti
v
e;
re
su
lt
s
o
f
m
o
d
el
w
er
e
ro
b
u
st
L
ie
v
en
s
et
al
.,
2
0
0
5
[2
4
]
B
el
g
iu
m
S
ta
g
e
I–
II
I
B
C
P
o
st
-o
p
er
at
iv
e
R
T
to
th
e
in
te
rn
al
m
am
m
ar
y
an
d
m
ed
ia
l
su
p
ra
cl
av
ic
u
la
r
ly
m
p
h
n
o
d
e
re
g
io
n
N
o
R
T
M
ar
k
o
v
m
o
d
el
R
T
w
as
co
st
ef
fe
ct
iv
e
w
h
en
ev
al
u
at
ed
o
v
er
a
lo
n
g
ti
m
e
p
er
io
d
in
tu
m
o
u
rs
w
it
h
a
sl
o
w
n
at
u
ra
l
h
is
to
ry
an
d
sy
st
em
ic
tx
fo
r
re
la
p
se
L
il
je
g
re
n
et
al
.,
1
9
9
7
[2
3
]
S
w
ed
en
U
n
if
o
ca
l
st
ag
e
I
B
C
p
o
st
se
ct
o
r
re
se
ct
io
n
an
d
ax
il
la
ry
d
is
se
ct
io
n
P
o
st
-o
p
er
at
iv
e
R
T
N
o
R
T
M
o
d
el
(d
ec
is
io
n
tr
ee
)-
b
as
ed
C
o
st
o
f
R
T
is
h
ig
h
;
re
su
lt
s
sh
o
w
th
e
im
p
o
rt
an
ce
o
f
id
en
ti
fy
in
g
ri
sk
fa
ct
o
rs
fo
r
lo
ca
l
re
cu
rr
en
ce
L
u
n
d
k
v
is
t
et
al
.,
2
0
0
5
[1
1
]
S
w
ed
en
B
C
(n
o
t
sp
ec
ifi
ed
)
P
ro
to
n
R
T
C
o
n
v
en
ti
o
n
al
R
T
M
ar
k
o
v
m
o
d
el
L
ik
el
y
th
at
p
ro
to
n
R
T
is
m
o
re
ap
p
ro
p
ri
at
e
fo
r
in
d
iv
id
u
al
s
w
it
h
h
ig
h
er
th
an
n
o
rm
ri
sk
o
f
C
V
D
M
ar
k
s
et
al
.,
1
9
9
9
[1
6
]
U
S
A
L
o
ca
l
re
g
io
n
al
re
la
p
se
n
o
d
e-
p
o
si
ti
v
e
B
C
R
T
N
o
R
T
E
E
u
si
n
g
d
at
a
fr
o
m
se
v
er
al
cl
in
ic
al
st
u
d
ie
s
C
o
st
p
er
lo
ca
l
re
g
io
n
al
re
la
p
se
p
re
v
en
te
d
d
ec
re
as
es
as
th
e
n
u
m
b
er
o
f
p
o
si
ti
v
e
ax
il
la
ry
n
o
d
es
in
cr
ea
se
s
P
at
ri
ce
et
al
.,
2
0
0
7
[1
7
]
U
S
A
E
ar
ly
-s
ta
g
e
B
C
R
T
p
lu
s
ta
m
o
x
if
en
T
am
o
x
if
en
al
o
n
e
M
ar
k
o
v
m
o
d
el
R
T
p
o
st
co
n
se
rv
at
iv
e
su
rg
er
y
w
as
co
st
ef
fe
ct
iv
e
in
o
ld
er
w
o
m
en
P
re
sc
o
tt
et
al
.,
2
0
0
7
[1
2
]
U
K
M
in
im
u
m
-r
is
k
(e
ld
er
ly
w
o
m
en
p
o
st
b
re
as
t-
co
n
se
rv
in
g
su
rg
er
y
)
W
h
o
le
b
re
as
t
R
T
N
o
R
T
M
ar
k
o
v
m
o
d
el
W
h
il
e
R
T
w
as
w
el
l
to
le
ra
te
d
w
it
h
n
o
im
p
ai
rm
en
t
o
n
o
v
er
al
l
Q
o
L
at
3
y
ea
rs
,
th
e
n
o
R
T
in
te
rv
en
ti
o
n
w
as
co
st
ef
fe
ct
iv
e
S
am
an
t
et
al
.,
2
0
0
1
[2
1
]
C
an
ad
a
H
ig
h
-r
is
k
(p
o
st
m
en
o
p
au
sa
l)
n
o
d
e-
p
o
si
ti
v
e
B
C
(p
o
st
m
as
te
ct
o
m
y
)
L
o
co
re
g
io
n
al
R
T
N
o
R
T
U
p
d
at
e
o
f
D
u
n
sc
o
m
b
e
et
al
.,
2
0
0
0
[ 2
1
]
R
T
ap
p
ea
rs
co
st
ef
fe
ct
iv
e,
b
u
t
fu
rt
h
er
an
al
y
se
s
n
ee
d
ed
S
h
er
et
al
.,
2
0
0
9
[1
8
]
U
S
A
E
ar
ly
-s
ta
g
e
es
tr
o
g
en
-
re
ce
p
to
r
p
o
si
ti
v
e
B
C
E
B
-P
B
I;
M
S
-P
B
I
W
B
R
T
M
ar
k
o
v
m
o
d
el
E
B
-P
B
I
is
co
st
ef
fe
ct
iv
e
v
s.
W
B
R
T
,
b
u
t
M
S
-P
B
I
is
n
o
t
an
d
is
u
n
li
k
el
y
to
b
e
co
st
ef
fe
ct
iv
e
u
n
le
ss
th
e
Q
o
L
af
te
r
M
S
-P
B
I
is
su
p
er
io
r
S
u
h
et
al
.,
2
0
0
5
[1
9
]
U
S
A
D
u
ct
al
ca
rc
in
o
m
a
in
si
tu
R
T
N
o
R
T
M
ar
k
o
v
m
o
d
el
A
d
d
it
io
n
o
f
R
T
fo
ll
o
w
in
g
B
C
S
fo
r
p
ts
w
it
h
d
u
ct
al
ca
rc
in
o
m
a
in
si
tu
sh
o
u
ld
n
o
t
b
e
w
it
h
h
el
d
b
ec
au
se
o
f
co
n
ce
rn
s
re
g
ar
d
in
g
it
s
co
st
ef
fe
ct
iv
en
es
s
C
o
lo
re
ct
a
l
ca
n
ce
r
D
ah
lb
er
g
et
al
.,
2
0
0
2
[2
6
]
S
w
ed
en
R
es
ec
ta
b
le
re
ct
al
ca
n
ce
r
P
re
o
p
er
at
iv
e
R
T
fo
ll
o
w
ed
b
y
su
rg
er
y
w
it
h
in
th
e
n
ex
t
w
ee
k
S
u
rg
er
y
w
it
h
o
u
t
R
T
E
E
al
o
n
g
si
d
e
cl
in
ic
al
tr
ia
l
P
re
o
p
er
at
iv
e
R
T
w
as
co
st
ef
fe
ct
iv
e
ev
en
u
si
n
g
th
ei
r
m
o
st
p
es
si
m
is
ti
c
as
su
m
p
ti
o
n
s
502 M. Barbieri et al.
T
a
b
le
1
co
n
ti
n
u
ed
R
ef
er
en
ce
s
S
et
ti
n
g
P
o
p
u
la
ti
o
n
In
te
rv
en
ti
o
n
C
o
m
p
ar
at
o
r
S
tu
d
y
d
es
ig
n
M
ai
n
fi
n
d
in
g
s
v
an
d
en
B
ri
n
k
et
al
.,
2
0
0
4
[2
5
]
T
h
e
N
et
h
er
la
n
d
s
R
es
ec
ta
b
le
re
ct
al
ca
n
ce
r
P
re
o
p
er
at
iv
e
R
T
w
it
h
T
M
E
T
M
E
w
it
h
o
u
t
p
re
o
p
er
at
iv
e
R
T
M
o
d
el
-b
as
ed
T
M
E
st
u
d
y
P
re
o
p
er
at
iv
e
R
T
w
as
b
o
th
ef
fe
ct
iv
e
an
d
co
st
ef
fe
ct
iv
e
P
ro
st
a
te
ca
n
ce
r
B
as
u
an
d
M
el
tz
er
,
2
0
0
5
[3
1
]
U
S
A
E
ar
ly
P
C
R
T
S
u
rg
er
y
(n
o
t
sp
ec
ifi
ed
),
W
W
M
o
d
el
(N
S
)
W
W
w
as
th
e
m
o
st
co
st
-e
ff
ec
ti
v
e
o
p
ti
o
n
g
iv
en
a
th
re
sh
o
ld
o
f
$
5
0
,0
0
0
p
er
Q
A
L
Y
H
u
m
m
el
et
al
.,
2
0
0
3
[2
8
]
U
K
E
ar
ly
lo
ca
li
se
d
(T
N
M
st
ag
es
1
an
d
2
)
P
C
T
ra
d
it
io
n
al
R
T
W
W
,
R
P
,
b
ra
ch
y
th
er
ap
y
,
3
D
-
C
R
T
,
cr
y
o
th
er
ap
y
M
ar
k
o
v
m
o
d
el
B
ra
ch
y
th
er
ap
y
an
d
3
D
-C
R
T
ap
p
ea
r
th
e
m
o
st
co
st
-e
ff
ec
ti
v
e
o
p
ti
o
n
s
b
u
t
h
ig
h
v
ar
ia
b
il
it
y
w
as
fo
u
n
d
K
o
n
sk
i
an
d
W
at
k
in
s-
B
ru
n
er
,
2
0
0
4
[3
2
]
U
S
A
H
o
rm
o
n
e-
re
fr
ac
to
ry
P
C
w
it
h
b
o
n
e
m
et
as
ta
se
s
S
F
X
,
M
F
X
P
ai
n
m
ed
ic
at
io
n
o
n
ly
,
ch
em
o
th
er
ap
y
(m
it
o
x
an
tr
o
n
e
o
r
p
re
d
n
is
o
n
e)
M
ar
k
o
v
m
o
d
el
S
F
X
w
as
th
e
m
o
st
co
st
-e
ff
ec
ti
v
e
o
p
ti
o
n
fo
r
p
al
li
at
iv
e
tx
K
o
n
sk
i
et
al
.,
2
0
0
5
(R
T
O
G
)
[3
4
]
U
S
A
T
re
at
m
en
t
o
f
lo
ca
ll
y
ad
v
an
ce
d
w
it
h
cl
in
ic
al
st
ag
e
T
2
b
,
T
2
c,
T
3
,
T
4
P
C
w
it
h
o
u
t
d
is
ta
n
t
m
et
as
ta
si
s
R
T
p
lu
s
h
o
rm
o
n
e
th
er
ap
y
R
T
M
ar
k
o
v
m
o
d
el
A
d
d
in
g
h
o
rm
o
n
e
to
R
T
p
ro
v
id
ed
g
o
o
d
v
al
u
e
fo
r
m
o
n
ey
K
o
n
sk
i
an
d
K
o
n
sk
i,
2
0
0
5
[3
3
]
U
S
A
C
li
n
ic
al
ly
lo
ca
li
se
d
P
C
I-
R
T
3
D
-C
R
T
M
ar
k
o
v
m
o
d
el
R
T
g
en
er
al
ly
co
st
ef
fe
ct
iv
e,
al
th
o
u
g
h
it
co
u
ld
b
e
le
ss
g
o
o
d
v
al
u
e
fo
r
m
o
n
ey
fo
r
o
ld
p
ts
an
d
o
v
er
a
sh
o
rt
-t
er
m
ti
m
e
h
o
ri
zo
n
K
o
n
sk
i
et
al
.,
2
0
0
6
[3
5
]
U
S
A
P
C
el
ig
ib
le
fo
r
su
rg
er
y
I-
R
T
3
D
M
ar
k
o
v
m
o
d
el
I-
R
T
co
u
ld
b
e
co
n
si
d
er
ed
co
st
ef
fe
ct
iv
e
at
th
e
u
p
p
er
li
m
it
o
f
ac
ce
p
ta
b
il
it
y
K
o
n
sk
i
et
al
.,
2
0
0
7
[2
9
]
U
S
A
In
te
rm
ed
ia
te
-r
is
k
P
C
I-
R
T
P
P
T
M
ar
k
o
v
m
o
d
el
P
P
T
is
n
o
t
co
st
ef
fe
ct
iv
e
in
m
o
st
p
ts
L
u
n
d
k
v
is
t
et
al
.,
2
0
0
5
[1
1
]
S
w
ed
en
U
n
sp
ec
ifi
ed
P
C
P
ro
to
n
th
er
ap
y
C
o
n
v
en
ti
o
n
al
R
T
M
ar
k
o
v
m
o
d
el
P
ro
to
n
th
er
ap
y
ap
p
ea
rs
a
co
st
-e
ff
ec
ti
v
e
o
p
ti
o
n
b
u
t
h
ig
h
v
ar
ia
ti
o
n
ar
o
u
n
d
m
ea
n
v
al
u
es
w
as
fo
u
n
d
N
ey
m
ar
k
et
al
.,
2
0
0
2
[2
7
]
F
ra
n
ce
P
C
ca
n
d
id
at
e
fo
r
su
rg
er
y
H
o
rm
o
n
al
th
er
ap
y
p
lu
s
ra
d
io
th
er
ap
y
(C
O
M
B
)
C
o
n
v
en
ti
o
n
al
R
T
E
E
w
it
h
d
at
a
fr
o
m
a
cl
in
ic
al
tr
ia
l
C
O
M
B
w
as
d
o
m
in
an
t
w
h
en
m
ea
n
su
rv
iv
al
ti
m
e
w
as
es
ti
m
at
ed
b
y
a
re
st
ri
ct
ed
m
ea
n
s
an
al
y
si
s
S
am
an
t
et
al
.,
2
0
0
3
[3
0
]
C
an
ad
a
L
o
ca
ll
y
ad
v
an
ce
d
P
C
A
d
ju
v
an
t
g
o
se
re
li
n
in
ad
d
it
io
n
to
R
T
R
T
E
E
w
it
h
d
at
a
fr
o
m
a
cl
in
ic
al
tr
ia
l
L
o
n
g
-t
er
m
ad
ju
v
an
t
g
o
se
re
li
n
p
ro
v
id
ed
g
o
o
d
v
al
u
e
fo
r
m
o
n
ey
H
ea
d
a
n
d
n
ec
k
ca
n
ce
r
H
ig
g
in
s,
2
0
1
1
[3
7
]
C
an
ad
a
E
ar
ly
g
lo
tt
is
(T
1
o
r
T
2
)
ca
n
ce
r
T
O
L
X
R
T
D
ec
is
io
n
tr
ee
m
o
d
el
-
b
as
ed
E
E
T
O
L
is
d
o
m
in
an
t
o
v
er
X
R
T
fo
r
th
is
g
ro
u
p
o
f
p
ts
w
it
h
ea
rl
y
ca
n
ce
r
K
o
n
sk
i
an
d
W
at
k
in
s-
B
ru
n
er
,
2
0
0
4
[ 3
2
]
U
S
A
L
o
ca
ll
y
ad
v
an
ce
d
H
N
S
C
C
A
F
X
C
,
A
H
F
X
S
,
H
F
X
S
ta
n
d
ar
d
fr
ac
ti
o
n
at
ed
R
T
M
ar
k
o
v
m
o
d
el
H
F
X
an
d
A
F
X
C
ap
p
ea
r
th
e
m
o
st
co
st
-
ef
fe
ct
iv
e
o
p
ti
o
n
s
L
u
n
d
k
v
is
t
et
al
.,
2
0
0
5
[1
1
]
S
w
ed
en
H
&
N
(u
n
sp
ec
ifi
ed
)
P
ro
to
n
th
er
ap
y
C
o
n
v
en
ti
o
n
al
R
T
M
ar
k
o
v
m
o
d
el
P
ro
to
n
th
er
ap
y
w
as
th
e
co
st
-e
ff
ec
ti
v
e
o
p
ti
o
n
A
F
X
C
ac
ce
le
ra
te
d
fr
ac
ti
o
n
at
ed
ra
d
io
th
er
ap
y
w
it
h
co
n
co
m
it
an
t
b
o
o
st
,
A
H
F
X
S
ac
ce
le
ra
te
d
an
d
fr
ac
ti
o
n
at
ed
ra
d
io
th
er
ap
y
w
it
h
sp
li
t,
B
C
b
re
as
t
ca
n
ce
r,
B
C
S
b
re
as
t-
co
n
se
rv
in
g
su
rg
er
y
,
C
V
D
ca
rd
io
v
as
cu
la
r
d
is
ea
se
,
E
B
-P
B
I
ex
te
rn
al
b
ea
m
p
ar
ti
al
b
re
as
t
ir
ra
d
ia
ti
o
n
,
E
E
ec
o
n
o
m
ic
ev
al
u
at
io
n
,
H
F
X
h
y
p
er
fr
ac
ti
o
n
at
ed
R
T
,
H
N
S
C
C
h
ea
d
an
d
n
ec
k
sq
u
am
o
u
s
ce
ll
ca
rc
in
o
m
a,
H
&
N
h
ea
d
an
d
n
ec
k
,
I-
R
T
in
te
n
si
ty
-m
o
d
u
la
te
d
R
T
,
M
F
X
m
u
lt
if
ra
ct
io
n
R
T
,
M
S
-P
B
I
M
am
m
o
S
it
e
p
ar
ti
al
b
re
as
t
ir
ra
d
ia
ti
o
n
,
N
S
n
o
t
sp
ec
ifi
ed
,
P
C
p
ro
st
at
e
ca
n
ce
r,
P
M
R
T
p
o
st
-m
as
te
ct
o
m
y
R
T
,
P
P
T
p
ro
to
n
-b
ea
m
th
er
ap
y
,
p
t(
s)
p
at
ie
n
t(
s)
,
Q
A
L
Y
q
u
al
it
y
-a
d
ju
st
ed
li
fe
-y
ea
r,
Q
o
L
q
u
al
it
y
o
f
li
fe
,
R
P
ra
d
ic
al
p
ro
st
at
ec
to
m
y
,
R
T
ra
d
io
th
er
ap
y
,
S
F
X
si
n
g
le
fr
ac
ti
o
n
R
T
,
T
N
M
tu
m
o
u
r,
n
o
d
e,
m
et
as
ta
si
s,
T
M
E
to
ta
l
m
es
o
re
ct
al
ex
ci
si
o
n
,
T
O
L
tr
an
s
o
ra
l
C
O
2
la
se
r
in
ci
si
o
n
,
tx
tr
ea
tm
en
t,
W
B
R
T
w
h
o
le
b
re
as
t
R
T
,
W
W
w
at
ch
fu
l
w
ai
ti
n
g
,
X
R
T
ex
te
rn
al
b
ea
m
ra
d
ia
ti
o
n
,
3
D
-C
R
T
th
re
e-
d
im
en
si
o
n
al
co
n
fo
rm
al
ra
d
ia
ti
o
n
th
er
ap
y
Quality of EEs of Radiotherapy in Cancer 503
with only 3 of 26 (10 %) analyses [12, 25, 28] using these
general population weights. In most cases (14 of 26, 54 %),
little detail on sources of valuation of HRQoL data was
provided and it is unclear whether these were taken from
the general public.
3.4 UK-Specific Requirements
Only two studies were conducted in the UK (Hummel et al.
[28] for prostate cancer and Prescott et al. [12] for breast
cancer). Therefore, the UK NHS and personal social ser-
vice costs and the UK setting were used in these analyses.
Prescott et al. [12] adopted a 3.5 % per annum discount
rate both for costs and for benefits while, in the Hummel
et al. [12] study, the NICE discount rate of 6 % for costs
and 1.5 % for benefits was used as they based their analysis
on an earlier NICE Reference Case (2001). The majority of
studies (24 of 29 [83 %]) used comparators relevant to the
UK, even though they were not developed for UK decision
makers specifically. Exceptions include studies by
Lundqvist et al. [11] (both for prostate and for head and
neck cancer) and Konski et al. [29] (who assessed the cost
effectiveness of proton-pump therapy, which are not fre-
quently used in the UK), and two studies on colorectal
cancer [25, 26], which considered interventions whose use
in the NHS currently varies widely.
As a number of the costs for the analyses were not
undertaken using British pounds sterling, the currency for
the cost-effectiveness estimates were converted using
standard currency conversion exchange rates (year 2012).
NICE’s cost-effectiveness threshold value was applied to
the studies to assess the value for money on the interven-
tions in the UK NHS. Incremental cost-effectiveness ratios
were not inflated since the objective of the analysis was to
assess whether these estimates were below the
£20,000–30,000 threshold at the time of each study. The
main intervention under analysis would be considered cost
effective in 16 (55 %) studies using a £20,000 threshold
and 19 (65 %) studies using a £30,000 threshold (Suh et al.
[19], Konski et al. [35] and Lundqvist et al. [11] for
prostate are those studies with cost-effectiveness ratios
between £20,000 and £30,000). On the basis of the NICE
threshold values, the following results could be synthes-
ised: in the case of breast cancer, whole breast radiotherapy
following breast conservation would be considered cost
effective compared with no radiotherapy, but further
studies are required to identify a very low-risk group of
patients who derive minimal benefit and can, therefore,
safely avoid radiotherapy. Post-mastectomy radiotherapy
would be considered cost effective compared with no
radiotherapy in patients at higher risk of recurrence.
However, the definition of this level of risk is not clear. For
colorectal cancer, preoperative radiotherapy followed by
surgery compared with surgery alone would be considered
cost effective. For prostate cancer, brachytherapy and
3-dimensional (3D) conformal radiation would be consid-
ered cost effective compared with traditional radiotherapy,
but intensity-modulated radiotherapy would be cost effec-
tive compared with 3D conformal radiation; radiotherapy
plus hormone therapy would be considered cost effective
compared with radiotherapy alone in locally advanced
patients; single or multi-fraction radiotherapy appears cost
effective compared with palliative treatments (pain medi-
cation or chemotherapy) in hormone-refractory metastatic
prostate cancer patients. Finally, for head and neck cancer,
accelerated fractionated radiotherapy with concomitant
boost, and hyper fractionated radiotherapy would be con-
sidered cost effective compared with standard fractionated
radiotherapy in patients with local advanced disease.
4 Discussion
The objective of this review was to identify and summarise
the evidence on the cost effectiveness of radiotherapy for
various cancers, and to assess methods quality in those
studies based on the NICE Reference Case. We observed
substantial heterogeneity in the methods used. Overall,
three key methods requirements considered essential for a
good-quality evaluation (effectiveness evidence based on a
systematic review, data for measurement of HRQoL
reported directly by patients and/or carers, use of PSA to
quantify the uncertainty) were generally not fulfilled. One
of these criteria, the failure to use PSA or equivalent using
individual-patient data from trials to characterise fully
evidential and other forms of uncertainty, may reflect that a
proportion of these studies was undertaken prior to the
general use of these methods. Although there are also few
examples in the later studies, it may be expected these
methods will be more commonly used in the future.
The failure of a large proportion of studies (18 of 26
[69 %]) to source HRQoL measurements from patients
probably reflects, in part, evidential weaknesses in the
underlying clinical data being used by the economic
evaluations in this review. In other words, when these
studies were undertaken, few HRQoL data were collected
in trials, particularly generic preference-based instruments
suitable for estimating QALYs. More recently, methods to
‘map’ HRQoL weights from disease-specific instruments
or clinical measures have been developed (Herna`ndez
Alava et al. [36]), and it may be expected they will be used
in future studies where there are no direct estimates of
suitable HRQoL weights. Where HRQoL weights are not
available to estimate QALYs, use of high-quality mapping
strategies can provide an informative approach to address
the gap [43].
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Arguably the most concerning method limitation is the
failure of most studies (26 of 29 [90 %]) to incorporate the
full extent of the available evidence on clinical effective-
ness into economic analyses using systematic review. A
general principle of evidence-based medicine, as well as
economic evaluation, is not to be selective with evidence.
However, in the review, many studies (12 of 29 [41 %])
used a single source of clinical-effectiveness evidence such
as a randomised trial. It is possible that single clinical
studies represent the only clinical evidence available in
some cases, but this was not discussed explicitly in the
papers. Where more than one clinical study has been
identified through a systematic review, evidence on effec-
tiveness for economic evaluation should be synthesised
using, for example, meta-analysis. At the very least, a
range of scenarios should be considered in the economic
Fig. 2 Quality of included studies compared with the NICE reference case. HRQoL health-related quality of life, NHS UK National Health
Service, NICE National Institute for Care and Excellence, QALY quality-adjusted life-year
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analysis using those different sources of clinical evidence.
However, in this review, a minority of studies used meta-
analysis or scenario analysis to bring in a fuller range of
clinical evidence.
In terms of relevance for UK decision makers, only two
studies were conducted in the UK and fully met the NICE
UK-specific requirements. It is difficult to judge the rele-
vance of the results of studies conducted in other juris-
dictions, especially due to differences in clinical practice
and sometimes in methods criteria specified by reim-
bursement and pricing agencies. Although most studies
included interventions that were relevant to UK clinical
practice at the time of publication, they might be dated due
to improvements in clinical techniques and less important
for current policy making. Radiotherapy techniques used in
the cancer areas investigated have evolved rapidly over the
last decade and many newer techniques are currently being
evaluated in clinical trials. In addition, the clinical evi-
dence in many of the studies is old and a number of new
trials describing novel radiotherapy interventions have
been reported, or are currently ongoing (e.g. CRO7 trial,
SUPREMO trial, TARGIT-A trial, Warde et al. [37–40]).
Essential and preferred methods requirements were
mainly taken from the NICE Reference Case, supported by
other guidelines (e.g. AMCP, CADTH, PBAC). NICE
represents an oft-cited independent, centralised authority
where decision making is informed by CEA. A strength of
NICE is the provision of an explicit cost-effectiveness
threshold to judge the value for money of the intervention
considered. Another point that is not explicitly defined in
the NICE Reference Case but is of considerable importance
is the impact of heterogeneity in the cost effectiveness of
treatments across different subgroups of patients. In the
case of cancer, the identification of specific types of
patients in whom radiotherapy is cost effective appears a
key issue. For example, in the case of breast cancer, an on-
going meta-analysis by the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) [41] of over 10,000
women treated in clinical trials with and without radio-
therapy, has shown that, overall, breast radiotherapy
reduces any cancer recurrence by 50 % [38]. However,
although the relative advantage for breast radiotherapy is
constant, the absolute benefit for individuals varies
depending on their risk of recurrence and this, in turn,
drives the cost effectiveness of radiotherapy in these
patients. It is likely that, in a very low-risk group of
patients, radiotherapy would not be cost effective. The
same can be stated of prostate cancer, in which the relative
merits of radiotherapy versus watchful waiting for low-risk
disease has not been tested but is unlikely to demonstrate
improvements in disease-specific survival up to 10 years of
follow-up, since a comparison of radical prostatectomy and
watchful waiting has shown no survival benefit [42].
In conclusion, based on this review, there is a dearth of
up-to-date, robust evidence on the effectiveness and cost
effectiveness of radiotherapy in cancer. The number of
published economic evaluations of radiotherapy using
QALYs or LYs saved appears quite low. For example, only
two studies were found for colorectal cancer, three for head
and neck cancer and none for cervical cancer. Some
essential methodological standards were generally not met,
especially in the identification of the clinical evidence.
Consequently, the full uncertainty associated with the
clinical benefits of the interventions was rarely captured.
Finally, few of the studies were based in the UK, and
international costs of interventions and healthcare use do
not generally transfer to the UK. As new, relevant evidence
becomes available, additional cost-effectiveness evalua-
tions should be undertaken to inform decision makers for
current and future clinical practice in this important area.
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Appendix 1: Search strategy for breast cancer
BREAST CANCER: RADIOTHERAPY
MEDLINE In-Process & Other Non-Indexed Citations
and MEDLINE: Ovid. 1946 to March Week 3 2012
4th April 2012
————————————————————
1. exp Breast Neoplasms/
2. ((breast$ or mamma$) adj25 (tumo?r$ or carcinoma$
or adenocarcinoma$ or sarcoma$ or oncolog$ or
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cancer$ or neoplas$ or malignan$ or metastasis or
polyp$ or lesion$ or growth$)).tw.
3. exp BREAST/
4. (tumo?r$ or carcinoma$ or adenocarcinoma$ or
sarcoma$ or oncolog$ or cancer$ or neoplas$ or
malignan$ or metastasis or metastases or polyp$ or
lesion$ or growth$).tw.
5. 3 and 4
6. (breast adj mass).tw.
7. (cystosarcoma adj phylloides).tw.
8. (intraductal adj carcinoma).tw.
9. (paget adj nipple adj disease).tw.
10. or/1–2,5–9
11. exp Radiotherapy/
12. radiotherap$.tw.
13. (radiation adj3 (therap$ or treatment$)).tw.
14. (radioimmunotherap$ or rit).tw.
15. Brachytherapy/
16. brachytherap$.tw.
17. 3d-crt.tw.
18. imrt.tw.
19. igrt.tw.
20. tomotherap$.tw.
21. radiosurger$.tw.
22. srs.tw.
23. sbrt.tw.
24. iort.tw.
25. scprt.tw.
26. exp Chemoradiotherapy/
27. chemoradiotherap$.tw.
28. chemo-radiotherap$.tw.
29. ccrt.tw.
30. or/11–29
31. 10 and 30
32. exp ‘‘Costs and Cost Analysis’’/
33. Economics/
34. exp economics, hospital/
35. exp economics, medical/
36. exp economics, dental/
37. Economics, nursing/
38. exp Models, Economic/
39. Economics, Pharmaceutical/
40. exp ‘‘Fees and Charges’’/
41. exp Budgets/
42. budget$.tw.
43. ec.fs.
44. cost$.ti.
45. (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimi$)).ab.
46. (economic$ or pharmacoeconomic$ or pharmaco-
economic$).ti.
47. (price$ or pricing$).tw.
48. (financial or finance or finances or financed).tw.
49. (fee or fees).tw.
50. (value adj2 (money or monetary)).tw.
51. quality-adjusted life years/
52. (qaly or qalys).af.
53. (quality adjusted life year or quality adjusted life
years).af.
54. or/32–53
55. letter.pt.
56. editorial.pt.
57. historical article.pt.
58. or/55–57
59. 54 not 58
60. Animals/
61. Humans/
62. 60 and 61
63. 60 not 62
64. 59 not 63
65. 31 and 64
Embase: Ovid. 1974 to 2012 April 03
4th April 2012
————————————————————
1. exp breast tumor/
2. ((breast$ or mamma$) adj25 (tumo?r$ or carcinoma$
or adenocarcinoma$ or sarcoma$ or oncolog$ or
cancer$ or neoplas$ or malignan$ or metastasis or
polyp$ or lesion$ or growth$)).tw.
3. exp breast/
4. (tumo?r$ or carcinoma$ or adenocarcinoma$ or
sarcoma$ or oncolog$ or cancer$ or neoplas$ or
malignan$ or metastasis or metastases or polyp$ or
lesion$ or growth$).tw.
5. 3 and 4
6. (breast adj mass).tw.
7. (cystosarcoma adj phylloides).tw.
8. (intraductal adj carcinoma).tw.
9. (paget adj nipple adj disease).tw.
10. or/1–2,5–8
11. exp radiotherapy/
12. exp radiotherapy/
13. radiotherap$.tw.
14. (radiation adj3 (therap$ or treatment$)).tw.
15. (radioimmunotherap$ or rit).tw.
16. brachytherapy/
17. brachytherap$.tw.
18. 3d-crt.tw.
19. imrt.tw.
20. igrt.tw.
21. tomotherap$.tw.
22. radiosurger$.tw.
23. srs.tw.
24. sbrt.tw.
25. iort.tw.
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26. scprt.tw.
27. exp chemoradiotherapy/
28. chemoradiotherap$.tw.
29. chemo-radiotherap$.tw.
30. ccrt.tw.
31. tomotherapy/
32. exp radiosurgery/
33. or/11–32
34. 10 and 33
35. ‘‘cost benefit analysis’’/
36. ‘‘cost-effectiveness analysis’’/
37. economics/
38. health economics/
39. pharmacoeconomics/
40. fee/
41. budget/
42. budget$.tw.
43. cost$.ti.
44. (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimi$)).ab.
45. (economic$ or pharmacoeconomic$ or pharmaco-
economic$).ti.
46. (price$ or pricing$).tw.
47. (financial or finance or finances or financed).tw.
48. (fee or fees).tw.
49. (value adj2 (money or monetary)).tw.
50. health care quality/
51. quality adjusted life year/
52. (qal or qalys).tw.
53. (quality adjusted life year or quality adjusted life
years).tw.
54. or/35–53
55. letter.pt.
56. editorial.pt.
57. historical article.pt.
58. or/55–57
59. 54 not 58
60. animals/
61. humans/
62. 60 and 61
63. 60 not 62
64. 59 not 63
65. 34 and 64
Cochrane Database of Systematic Reviews (CDR):
Wiley Interscience. 1996-present
NHS Economic Evaluation Database (NHS EED):
Wiley Interscience. 1995-present
Health Technology Assessment Database (HTA):
Wiley Interscience. 1995-present
Database of Abstracts of Reviews of Effects
(DARE)): Wiley Interscience. 1995-present
10th April 2012
————————————————————
ID Search
#1 MeSH descriptor Breast Neoplasms explode all trees
#2 (breast* OR mamma*):ti,ab,kw
#3 MeSH descriptor Breast explode all trees
#4 (#2 OR #3)
#5 (tumor* or tumour* or carcinoma* or
adenocarcinoma* or sarcoma* or oncolog* or
cancer* or neoplas* or malignan* or metastasis or
metastases or polyp* or lesion* or growth*):ti,ab,kw
#6 (#4 AND #5)
#7 (breast mass):ti,ab,kw
#8 (cystosarcoma phylloides):ti,ab,kw
#9 (intraductal carcinoma):ti,ab,kw
#10 (paget nipple disease):ti,ab,kw
#11 (#1 OR #6 OR #7 OR #9 OR #10)
#12 MeSH descriptor Radiotherapy explode all trees
#13 (radiotherap*):ti,ab,kw
#14 (radiation therap*):ti,ab,kw
#15 (radiation treatment*):ti,ab,kw
#16 (radioimmunotherap* or rit):ti,ab,kw
#17 MeSH descriptor Brachytherapy explode all trees
#18 (brachytherap*):ti,ab,kw
#19 (3d-crt or imrt or igrt or tomotherap* or radiosurger*
or srs or sbrt or iort or scprt):ti,ab,kw
#20 MeSH descriptor Chemoradiotherapy explode all
trees
#21 (chemoradiotherap* or chemo-radiotherap* or ccrt):
ti,ab,kw
#22 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR
#18 OR #19 OR #20 OR #21)
#23 (#11 AND #22)
EconLit: Ovid. 1961 to February 2012
4th April 2012
————————————————————
1. ((breast$ or mamma$) adj25 (tumo?r$ or carcinoma$
or adenocarcinoma$ or sarcoma$ or oncolog$ or
cancer$ or neoplas$ or malignan$ or metastasis or
polyp$ or lesion$ or growth$)).tw.
2. (breast adj mass).tw.
3. (cystosarcoma adj phylloides).tw.
4. (intraductal adj carcinoma).tw.
5. (paget adj nipple adj disease).tw.
6. or/1–5
7. radiotherap$.tw.
8. (radiation adj3 (therap$ or treatment$)).tw.
9. (radioimmunotherap$ or rit).tw.
10. brachytherap$.tw.
11. 3d-crt.tw.
12. imrt.tw.
13. igrt.tw.
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14. tomotherap$.tw.
15. radiosurger$.tw.
16. srs.tw.
17. sbrt.tw.
18. iort.tw.
19. scprt.tw.
20. chemoradiotherap$.tw.
21. chemo-radiotherap$.tw.
22. ccrt.tw.
23. or/7–22
24. 6 and 23
Conference Proceedings Index (CPI): Web of Science.
1990-present
10th April 2012
————————————————————
#9. #8 AND #7
#8. TS=(economics or pharmacoeconomics or fee or
budget* or cost* or pharmaco-economics or price* or
pricing* or financial or finance or finances or financed or
fee or fees or value money or value monetary or health care
quality or quality adjusted life year* or qaly or qalys)
#7. #6 AND #5
#6. TS=(radiotherap* or radiation therap* or radiation
treatment* or radioimmunotherap* or rit or brachythe-
rap* or 3d-crt or imrt or igrt or tomotherap* or
radiosurger* or srs or sbrt or iort or scprt or chemora-
diotherap* or chemo-radiotherap* or ccrt)
#5. #4 OR #3
#4. TS=(breast mass or cystosarcoma phylloides or
intraductal carcinoma or paget nipple disease)
#3. #2 AND #1
#2. TS=(tumor* or tumour* or carcinoma* or adenocar-
cinoma* or sarcoma* or oncolog* or cancer* or
neoplas* or malignan* or metastasis or metastases or
polyp* or lesion* or growth*)
#1. TS=(breast* or mamma*)
Searching the Cost-effectiveness Registry (https://
research.tufts-nemc.org/cear4/Home.aspx)
10th April 2012
Searched for ‘‘breast cancer’’
165 results, scanned titles for relevance, all relevant
references were already in the database.
NICE website search
11th April 2012
Breast Cancer (early & locally advanced) (CG80) http://
www.nice.org.uk/_gs/searchtracker/GUIDANCE/12132
Interstitial laser therapy for breastcancer (IPG89) http://
www.nice.org.uk/_gs/searchtracker/GUIDANCE/11035
Endoscopic mastectomy and endoscopic wide local
excision forbreast cancer (IPG296) http://www.nice.org.
uk/_gs/searchtracker/GUIDANCE/12081
Endoscopic axillary lymph node retrieval for breast
cancer (IPG147) http://www.nice.org.uk/_gs/searchtracker/
GUIDANCE/11026
Brachytherapy as the sole method of adjuvant radio-
therapy for breast cancerafter local excision (IPG268)
http://publications.nice.org.uk/brachytherapy-as-the-sole-
method-of-adjuvant-radiotherapy-for-breast-cancer-after-
local-excision-ipg268
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